This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Pediatric Ophthalmology  • Retinal/ Chorioretinal Disorders  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic

Lingkun Kong, MD, PhD; Helen A. Mintz-Hittner, MD; Rebecca L. Penland, MS; Francis L. Kretzer, PhD; Patricia Chévez-Barrios, MD

Arch Ophthalmol. 2008;126(8):1161-1163.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Overexpression of vascular endothelial growth factor (VEGF) appears important in the pathogenesis of retinopathy of prematurity (ROP). Bevacizumab (Avastin; Genentech, Inc, South San Francisco, California) is a recombinant humanized monoclonal IgG1 antibody. It binds to and inhibits the biological activity of human VEGF.¹ It has been estimated that more than 10 000 patients worldwide have been treated with intravitreous bevacizumab.² We report results of a study in postmortem eyes with intravitreous bevacizumab treatment for zone 1, stage 2+ ROP in an extremely low-birth-weight infant.

Report of a Case

The protocol was approved by the institutional review board for the use of intravitreous injections of bevacizumab vs conventional laser therapy for the treatment of vision-threatening ROP.

A Hispanic boy delivered at 22 weeks' gestation weighing 350 g had hypoxia at birth with development of many multisystem complications . . . [Full Text of this Article]

Comment

AUTHOR INFORMATION